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Abstract
The human P2Y14 receptor is potently activated by UDP-glucose (UDP-Glc), UDP-galactose (UDP-
Gal), UDP-N-acetylglucosamine (UDP-GlcNAc), and UDP-glucuronic acid. Recently, cellular
release of UDP-Glc and UDP-GlcNAc has been reported, but whether additional UDP-sugars are
endogenous agonists for the P2Y14 receptor remains poorly defined. In the present study, we describe
an assay for the quantification of UDP-Gal with sub-nanomolar sensitivity. This assay is based on
the enzymatic conversion of UDP-Gal to UDP, using 1–4-β-galactosyltransferase. UDP is
subsequently phosphorylated by nucleoside diphosphokinase in the presence of [γ32P]ATP and the
formation of [γ32P]UTP is monitored by high performance liquid chromatography. The overall
conversion of UDP-Gal to [γ32P]UTP was linear between 0.5 and 30 nM UDP-Gal. Extracellular
UDP-Gal was detected on resting cultures of various cell types, and increased release of UDP-Gal
was observed in 1321N1 human astrocytoma cells stimulated with the protease-activated receptor
agonist thrombin. Occurrence of regulated release of UDP-Gal suggests that, in addition to its role
in glycosylation reactions, UDP-Gal is an important extracellular signaling molecule.
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INTRODUCTORY STATEMENT
Nucleotides and nucleotide-sugars are released as extracellular signaling molecules in most
tissues, effecting a broad range of physiologically important responses via activation of P2X
and P2Y purinergic receptors [1;2]. P2X receptors, comprising seven species (P2X1–P2X7),
are ATP-gated ion channels. P2Y receptors belong to the superfamily of G protein-coupled
receptors. At least eight P2Y receptor species have been identified in humans, seven of which
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13) are activated by adenine and/or uridine
nucleoside di- and tri-phosphates [2]. The P2Y14 receptor was identified as the eighth
legitimate member of the P2Y family [3;4]. Unlike other P2 receptors, the human P2Y14
receptor is not activated by di- or tri-phosphonucleotides. Instead, the P2Y14 receptor is
activated with relatively similar potencies by UDP-glucose (UDP-Glc)1, UDP-galactose
(UDP-Gal), UDP-N-acetylgluosamine (UDP-GlcNAc), and UDP-glucuronic acid [3;5].
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P2Y14 receptor transcripts are expressed in a broad range of human tissues, including brain,
stomach, intestine, adipose, lung, spleen, and heart, and also in specialized cells such as
circulating neutrophils and lymphocytes [3;6–8]. UDP-sugar-promoted signaling has been
reported in astrocytes and microglial cells [9;10], lung epithelial cells [11], bone marrow
hematopoietic stem cells [12], and multiple types of peripheral immune cells, including
neutrophils, lymphocytes, and dendritic cells [5;7;8;13;14]. These observations suggest that
UDP-sugars, high-energy donor substrates in biosynthetic reactions, are released from cells in
a regulated fashion to play autocrine/paracrine signaling roles.
Recently, we demonstrated that UDP-Glc and UDP-GlcNAc are released from cells under
various physiological conditions [15–19], but whether other UDP-sugars are endogenous
agonist(s) for the P2Y14 receptor remains to be elucidated. Several high performance liquid
chromatography (HPLC) systems have been developed to resolve UDP-sugars from each other
and from other nucleotides. However, a major problem in assessing nucleotides and nucleotide-
sugars in extracellular solutions is that experimental conditions often require substantial
dilution of the bathing medium, resulting in nucleotide concentrations that are below threshold
values for standard HPLC-coupled detectors, such as UV (λ = 260 nm) or conductimetric
detectors. We have recently circumvented this limitation for the measurement of UDP-Glc and
UDP-GlcNAc by monitoring the UDP-Glc- and the UDP-GlcNAc-dependent conversion of
[32P]PPi to [32P]UTP, using UDP-Glc pyrophosphorylase and UDP-GlcNAc
pyrophophorylase (AGX2), respectively [15–19]. In the present study, we describe an
enzymatic assay that quantifies UDP-Gal with sub-nanomolar sensitivity. Using this assay, we
investigated the presence of UDP-Gal in extracellular solutions on resting cells as well as in
cells exposed to physiologically relevant stimuli.
MATERIALS AND METHODS
Reagents
UDP-Gal, α-lactalbumin, and nucleoside diphosphokinase (NDPK, EC 2.7.4.6) from Bakers
yeast were purchased from Sigma. UDP-[3H]Gal (18 Ci/mmol) [3H]glucose (22 Ci/mmol),
[D-glucose-114C]lactose (57 mCi/mmol), and [γ32P]ATP (3000 Ci/mmol) were obtained from
Amersham Biosciences. Bovine recombinant 1,4-β-galactosyltransferase (4βGT, E.C.2.4.1.2)
was purchased from Calbiochem. All other reagents were of the highest purity available, as
previously described [17;19].
Cell cultures and incubations
Polarized cultures of well-differentiated primary human bronchial epithelial (HBE) cells and
Madin-Darby canine kidney (MDCK) cells were grown on 12-mm Transwell supports
(Costar), as previously described [15;19]. A549 lung epithelial, 1321N1 human astrocytoma,
and MCF-7 mammary carcinoma cells were grown on 24-well plastic plates (1.1 cm2 per well).
Cultures were rinsed three times with Dulbecco’s modified essential medium (DMEM)
containing 4.5 g/L glucose DMEM-H and allow to rest in 300 μl (DMEM-H) for 1 h at 37°C
in a humidified incubator supplemented with 5% CO2 (HBE and MDCK cells were incubated
in 300 μl mucosal and 500 μl basolateral DMEM-H). After the indicated incubation, 250 μl
medium (mucosal medium in the case of HBE and MDCK cells) was sampled and rapidly
centrifuged to remove potentially detached cells. Supernatants were heated at 95°C for 2 min,
and either used immediately or stored at −20°C. For intracellular measurements, cultures were
lysed with 5% trichloroacetic acid, which was subsequently extracted with ethylic ether, as
described [15;19].
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The conversion of UDP-Gal to lactose was assessed in 100 μl HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)-buffered DMEM-H (pH 7.4). Lactalbumin (0.2 mg/ml) was
included in the lactose synthetase reaction, as indicated. The conversion of UDP-Gal to N-
acetyllactosamine was assessed in 100 μl glucose-free HEPES-buffered DMEM (pH 7.4)
supplemented with the indicated amount of N-acetylglucosamine. Lactalbumin was omitted
from these incubations. All 4βGT-catalyzed reactions were performed in the presence of 5 mM
MnCl2 and the indicated amount of 4βGT (typically, 0.002 U/ml) and substrates. Except as
indicated otherwise, incubations were initiated by the addition of 4βGT and they were allowed
for 30 min at 30°C. Incubations were terminated by heating the samples for 2 min at 95°C.
Samples were transferred to ice and either analyzed immediately or stored at −20°C. Species
were separated by HPLC.
UDP-sugar hydrolysis
1321N1 cells were incubated in the presence of 0.1 μCi UDP-[3H]Gal or UDP-[3H]Glc.
Samples were collected at the indicated times and heated for 2 min at 95°C to inactivate
enzymatic activities potentially released from cells. Radioactive species were analyzed by
HPLC.
NDPK-catalyzed phosphorylation of UDP
Unless indicated otherwise, incubations (5 min at 30 °C) were performed in 100 μl DMEM-H
containing 0.1 U/ml NDPK and 0.1 μC [γ32P]ATP (~200,000 cpm, 100 nM) and the indicated
amount of UDP. The conversion of [32P]ATP to [32P]UTP was monitored by HPLC. To assess
UDP generated from UDP-Gal released from cells, the NDPK-catalyzed reaction was preceded
by a 30 min incubation of samples with or without 0.002 U/ml 4βGT, as described above. The
[32P]UTP values obtained in the absence of 4βGT were used to calculate UDP levels, and were
subtracted from those obtained in the presence of 4βGT to calculate UDP-Gal concentrations.
HPLC analysis
Species were separated by HPLC (Shimadzu), using the columns and solvents indicated below.
The HPLC apparatus was equipped with a Radiometer Flow-One® Beta detector (Packard)
and a SPD-10A UV detector (Shimadzu), and radioactivity and absorbance at λ = 260 nm were
monitored on-line as described previously [19]. Briefly, the area of radioactive peaks was
quantified using the Flo-One for Windows Radio-HPLC application software (Packard).
[32P]- and [3H]-radioactivity were measured by Cerenkov and liquid scintillography,
respectively. [32P]-peaks displaying >750 cpm (background [32P]-background <250 cpm) and
[3H]-species displaying >500 cpm ([3H]-background < 150 cpm) were analyzed (signal-to-
noise-ratio >3). UDP-[3H]Gal was separated from [H3]lactose or N-[H3]acetyllactosamine
(4βGT reaction) or from [3H]galactose-1P and[3H]galactose (UDP-sugar hydrolysis) using a
Nova-Pack C18 column (Waters) with an ion pairing mobile phase (1 ml/min) consisting of 8
mM tetrabutylammonium hydrogen sulfate and (TBEAHS) and 17 mM H2KPO4 (pH 5.3) in
10% methanol for the initial 5 min, and 8 mM TBEAHS (pH 5.3) and 100 mM H2KPO4 in
10% methanol for additional 10 min. The elution times of [3H]galactose, [3H]galactose-1P,
[H3]lactose, N-[H3]acetyllactosamine, and UDP-[3H]Gal were 1.9, 2.5, 3.2, 3.6, and, 8.8 min,
respectively. Using this HPLC system, UDP-[3H]Glc, [3H]glucose, and [3H]glucose-1P eluted
at 9.2, 1.8, and 2.5, respectively. N-[14C]acetyglucosamine and N-[14C]acetyllactosamine were
resolved from each other using a Kromasil-NH2 column (Alltech) and 75% (v/v) acetonitrile
as the mobile phase (1 ml/min). The elution times were 5.8 min for N[3H]acetylglucosamine
and 8.4 min for N-[3H]acetyllactosamine. [32PATP and [32P]UTP were resolved via a Hamilton
PRP-X100 anion exchange column with a mobile phase (1 ml/min) consisting of 150 mM M
NH4HCO3 (pH 8.5) in 30% methanol. UTP and ATP eluted at 8.4 and 13.5 min, respectively.
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ATP and UDP-Glc measurements
The mass of ATP and UDP-Glc were assessed using the luciferin-luciferase assay and the UDP-
Glc pyrophosphorylase reaction, respectively, as previously described [18].
Data analysis
The Sigma Plot 10.0 software was used for data analysis. The data displayed in Figures 3C
and D were fitted according to a fist-order regreation line (y = b + a; where y represents the %
UTP formation, x is the substrate concentration, b is the intercept of y0 on the y-axis, and a is
the slope of the curve). The b, a, and regression coefficient squared (r2) values are indicated
in the legend of the Figure. The half-life (t0.5) values for UDP-sugar decay (Figure 4B) were
calculated as t0.5 = 0.693/k (k is the first-order rate constant), as previously described [20].
Statistical significance (by Student’s t test) was defined as p < 0.01.
RESULTS
Synthesis of lactose and N-acetyllactosamine using galactosyltransferase
1,4-β-Galactosyltransferase (4βGT) from bovine milk, also known as lactose synthetase,
transfers galactose from UDP-Gal to lactose, using glucose as acceptor substrate in the presence
of α-lactalbumin (equation Ia). In the absence of α-lactalbumin, N-acetyglucosamine is the
preferred acceptor substrate of 4βGT and lactosamine is a product of this reaction [21], as
described in equation IIa.
Ia
IIa
While a number of protocols take advantage of the above reactions to assess 4βGT activity in
tissues and subcellular compartments, our goal was to use purified 4βGT to quantify UDP-Gal
in extracellular solutions. Based on previous measurements of extracellular nucleotides and
nucleotide-sugars [19;22], UDP-Gal concentration in bulk extracellular solutions bathing cell
cultures likely would be within the low nanomolar range, below the range of sensitivity of
standard UV detectors. Therefore, we examined the possibility of using radiolabeled substrates
to develop a 4βGT-based assay that would measure the UDP-Gal-dependent formation of
radiolabeled lactose or N-acetyllactosamine, with high sensitivity. For an initial evaluation of
the efficiency of 4βGT to catalyze the conversion of nanomolar amounts of UDP-Gal to either
lactose or N-acetyllactosamine, UDP-[3H]Gal was used as a radiotracer, and the formation of
[3H]-labeled products (Ib and IIb) was monitored by HPLC.
Ib
IIb
Reaction Ib was assessed in a standard glucose-containing tissue culture medium (DMEM-H)
supplemented with 0.2 mg/ml α-lactalbumin and 5 mM MnCl2. A 60 min incubation of 0.002
U/ml 4βGT with 0.1 μCi (100 nM) UDP-[3H]Gal resulted in full conversion of UDP-[3H]Gal
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to [3H]lactose (Fig. 1A). The enzyme concentration-effect relationship for the lactose
formation reaction is shown in Figure 1B and the time-course is illustrated in Figure 1C. As
previously established for this reaction [21], conversion of UDP-[3H]Gal to [3H]lactose was
negligible in the absence of α-lactalbumin (Fig. 1D).
The 4 GT-catalyzed reaction was highly efficient at all UDP-Gal concentrations tested within
the 1–1000 nM range (Fig. 2A). In contrast, and consistent with the high selectivity that 4 GT
exhibits towards UDP-Gal over other UDP-sugars [21;23], UDP-[3H]Glc (1–1000 nM) was
recovered unchanged after a 30 min incubation with 4 GT (Fig. 2A). Thus, the lactose
synthetase reaction described above quantitatively transfers galactose from UDP-Gal to
lactose. However, the presence of millimolar amounts of glucose in most tissue culture media
and biological samples posed a limitation for assessing UDP-Gal mass with high sensitivity,
using radiolabeled glucose as radiotracer. Furthermore, using conditions (enzyme
concentration, incubation time, and temperature) similar to those used above for lactose
synthesis, efficient conversion of UDP-[3H]Gal (100 nM) to [3H]N-acetyllactosamine was
achived only at ≥ 100 μM N-acetyglucosamine (Fig. 2B). Thus, practical reasons prevented us
from using high specific activity radiolabeled glucose or N-acetylglucosamine as a probe for
the UDP-Gal-dependent formation of lactose or N-acetyllactosamine.
NDPK-catalyzed phosphorylation of UDP
To overcome the limitations associated with the use of radiolabeled acceptor substrate in the
4βGT reaction, we investigated the possibility of measuring the formation of UDP (rather than
lactose or lactosamine) as an alternative assay for UDP-Gal mass quantification. We have
previously used NDPK to synthesize UTPγS in the presence of UDP and ATPγS [24]. Based
on this and other observations [20], we recently envisioned an assay that uses NDPK to quantify
the UDP-dependent conversion of [γ32P]ATP to [γ32P]UTP [25]. Therefore, we reasoned that
combining the 4βGT-catalyzed reaction (Ia) with the NDPK-based phosphorylation of UDP
(reaction IIIa) would provide a reliable tool for the high sensitive measurement of UDP-Gal.
Ia
IIIa
To optimize the NDPK-based assay, the enzyme concentration dependence and the time course
of the reaction were assessed, and a 10-fold excess of ATP mass, relative to UDP, was added
to drive the reaction towards [γ32P]UTP synthesis. Figure 3A indicates that, in the presence of
100 nM [γ32P]ATP, 10 nM UDP was nearly completely converted to [γ32P]UTP, using 0.1 U/
ml NDPK (5 min). Under these enzyme and substrate concentrations, the reaction reached
steady state (8–9% conversion of [γ32P]ATP to [γ32P]UTP) within the first min (Fig. 3B). A
calibration curve for UDP (using 0.1 U/ml NDPK, 100 nM [γ32P]ATP, 5 min at 30°C) is
illustrated in Figure 3C. As little as 0.5 nM UDP could be detected with this assay (i.e., with
a signal-to-noise ratio >3), and the reaction was linear to up to 30 nM UDP (Fig. 3C and data
not shown). Linearity could be expanded to 100 nM UDP by increasing the concentration of
[γ32P]ATP to 300 nM (not shown).
Lastly, the suitability of combining 4βGT and NDPK for the quantification of UDP-Gal was
examined. Samples containing various concentrations of UDP-Gal in DMEM-H were
incubated for 30 min in the absence or presence of 0.002 U/ml 4βGT, and 0.1 U/ml NDPK and
100 nM [γ32P]ATP were subsequently added for an additional 5 min. As predicted, using UDP-
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Gal as starting substrate, conversion of 100 nM [γ32P]ATP to [32P]UTP by NDPK was
absolutely dependent on the presence of 4βGT (Fig. 3D). The overall reaction displayed a
sensitivity limit of 0.5 nM UDP-Gal and linearity was observed to up 30 nM UDP-Gal.
Linearity could be expanded to 100 nM UDP-Gal by increasing the concentration of [γ32P]
ATP to 300 nM.
Cellular release of UDP-Gal
Having optimized conditions for the measurement of nanomolar amounts of UDP-Gal, we
asked whether this UDP-sugar could be detected in the extracellular medium of culture cell
models. Primary cultures of human bronchial epithelial (HBE) cells and various cell lines were
rinsed and incubated undisturbed for 1 h in DMEM-H (0.3 ml/cm2). The medium was collected
and samples were subsequently incubated for 30 min either with or without 4βGT, followed
by a 5 min incubation with NDPK and [γ32P]ATP, as described above. UDP-Gal concentrations
were calculated as the difference in [32P]UTP formation observed between samples pre-
incubated with or without 4βGT. For comparison, UDP-Glc and ATP also were measured in
these samples, using protocols previously described [19]. Extracellular UDP-Gal was present
in detectable amounts under resting conditions on well-differentiated primary HBE cells and
various cell lines, but was not detected (i.e., <0.5 nM) on resting human astrocytoma 1321N1
cells (Table 1). Differences in the mechanisms of release and extracellular metabolism likely
accounted for the range of nucleotide levels observed within a given culture and among cell
types.
An important question regarding the extracellular accumulation of UDP-Gal is whether this
nucleotide-sugar is released from cells in response to physiological stimuli. Thrombin, a serine
protease, promotes release of ATP and UDP-Glc from human astrocytoma cells, via activation
of protease-activated receptor-1 [17;26;27]. Therefore, we took advantage of this cell model
to ask to what extent thrombin-elicited UDP-Glc release is accompanied by the release of UDP-
Gal. Incubation of 1321N1 cells with thrombin (20 nM, 5 min) resulted in a enhanced
accumulation of extracellular UDP-Gal, i.e., from <0.5 nM to 2.3 ± 0.8 nM (Fig. 4A). The
amount of UDP-Gal release detected in response to thrombin stimulation was 690 ± 242 fmol/
well (~ 7 × 105 cells), which represented approximately 0.46% of the total cellular content of
this UDP-sugar (140 pmol/well). For comparison, the increase in UDP-Glc mass in thrombin-
stimulated cells represented 1090 ± 165 fmoles, a 0.36% of the cellular UDP-Glc content (305
pmol/well). Thus, relative to their intracellular levels, UDP-Gal release from thrombin-
stimulated 1321N1 cells was similar (although not identical) to UDP-Glc release, suggesting
a mechanism of release that reflects the relative cellular abundance of these species.
It is worth nothing, however, that our measurements may have considerably underestimated
the actual mass of UDP-sugar released from thrombin-stimulated cells, due to an ecto-
nucleotide pyrophosphorylase (e-NPP) activity expressed on these cells [Fig. 4B and [20;
28]]. Indeed, changes in extracellular levels of UDP-Glc (Fig. 4A) and ATP (1360 ± 220 pmol/
well) in response to thrombin stimulation were considerably less robust than those previously
assessed in the presence of the e-NPP inhibitor β, γ-methylene ATP [17;28]. Extracellular UDP
levels increased not significantly after thrombin addition (control, 2.4 ± 0.6 nM; thrombin, 3.1
± 1.2 nM). However, we have not included β,γ-methylene ATP or other ecto-nucleotidase
inhibitors in our incubations due to interferences with the NDPK-based reaction used in the
UDP-Gal assay (not shown). Importantly, differences in extracellular UDP-Gal vs. UDP-Glc
levels unlikely reflected differences in metabolism rates between these species, since [3H]
UDP-Gal and [3H]UDP-Glc were metabolized on 1321N1 cells with nearly identical half-life
values (8.7 and 9.9 min, respectively, Figure 4B).
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The enzymatic assay for UDP-Gal mass described here provides a highly sensitive and selective
approach for the quantification of this UDP-sugar in diluted biological samples. Early works
by Hull and Montgomery detected UDP-Gal in cell lysates with a sensitivity of 50 pmoles,
using an ion exchange HPLC method coupled with conductimetric detection [29]. Using a UV/
absorbance (λ = 260 nm) detector coupled to an ion exchange HPLC column, Tomiya et al.
separated and quantified various nucleotide-sugars, including UDP-Gal, with a detection limit
of approximately 1 pmol [30]. However, Kochanowski et al. illustrated that the lowest UDP-
Gal concentration in cell extracts capable of giving a reliable signal-to-noise ratio is 15 pmoles
[31]. The sensitivities of these previously published methods are not good enough to quantify
sub-nanomolar concentrations of UDP-Gal. The assay described in the current study uses
4βGT to selectively convert UDP-Gal to UDP, and UDP is subsequently phosphorylated by
NDPK using [γ32P]ATP as a radiolabeled substrate. The sensitivity of this assay (50 fmol/
injection or 0.5 nM in 100 μl) is markedly greater than those previously reported. Importantly,
applying the protocol described here, we quantified for the first time UDP-Gal in extracellular
solutions and demonstrated the occurrence of cellular release of UDP-Gal from astrocyte-like
cells in response to a physiologically relevant stimulus. Demonstration of regulated release of
UDP-Gal expands previous observations with UDP-Glc and UDP-GlcNAc [17;19], providing
further support for the physiological significance of the P2Y14 receptor.
Earlier studies in glycobiology have indirectly suggested that release of cellular nucleotide-
sugars might occur. For example, extracellular glycosyltransferase activity [32;33] was
detected and extracellular glycosylation was speculated to regulate intercellular adhesion. This
idea has not been unambiguously supported by other studies [reviewed in [34]]. More recently,
however, Stosell and co-workers [35] illustrated that platelet surface-associated β-1,4-
galactosyltransferase produced efficient galactosylation on exposed β-GlcNAc residues when
UDP-Gal was added to the platelet suspension. This observation, together with our
demonstration that UDP-Glc, UDP-GlcNAc, and now UDP-Gal are released from cells in a
regulated manner, reopens the question of whether extracellular UDP-sugars serve
extracellular roles in addition to actions as activators of G protein-coupled receptors.
We have not addressed the issue of the mechanism of UDP-Gal release, but an attractive
hypothesis is that the lumen of the secretory pathway is an important source of extracellular
UDP-sugars. UDP-sugars are synthesized in the cytosol and transported to the lumen of the
endoplasmic reticulum (ER) and/or Golgi apparatus to serve as sugar donors for
glycosyltransferase-catalyzed reactions. ER/Golgi-resident nucleotide sugar transporters
translocate cytosolic UDP-sugars to these organelles, using luminal UMP as antiporter
substrate [36]. UDP-sugars imported to the ER/Golgi reach concentrations up to 20-fold higher
than cytosolic levels [36]. Since ER/Golgi nucleotide-sugars are not transported back to the
cytosol, potentially they can be delivered as cargo molecules and released from cells, e.g.,
during export/secretion of glycoconjugates. Hence, vesicular UDP-sugar release should be
highly dependent on the ER/Golgi expression of the cognate transporter. Indeed, we have
recently demonstrated that ER/Golgi UDP-GlcNAc transporters contribute to the release of
UDP-GlcNAc from epithelial cells and yeast [19].
In conclusion, we describe a novel assay that allows the quantification of UDP-Gal with sub-
nanomolar sensitivity. We have demonstrated that UDP-Gal, a potent agonist at the cell surface
P2Y14 receptor, is present in the conditioned medium of various cell models, including
physiologically relevant primary cultures of human bronchial epithelial cells. We also
illustrated that enhanced release of UDP-Gal occurs under physiological/pathophysiological
conditions, such as in thrombin-stimulated astrocytes. Given the likelihood that release of the
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activating P2Y14 receptor ligand may differ according to cell type, UDP-Gal predictably is an
important autocrine/paracrine regulator of P2Y14 receptor activity.
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Figure 1. Enzymatic conversion of UDP-[3H]Gal to [3H]lactose
A, HPLC tracings illustrating the conversion of UDP-[3H]Gal to [3H]lactose ([3H]Lac) in the
presence (bottom) or in the absence (top) of 4βGT (0.002 U/ml, 60 min, 30°C). B, incubations
were for 60 min at 30°C in the presence of the indicated amount of 4βGT. C, the time-course
of the reaction was examined using 0.002 U/ml 4βGT. D, the conversion of UDP-[3H]Gal to
[3H]lactose was assessed in the absence (-) or presence (+) of 0.2 mg/ml α-lactalbumin. All
reactions were performed in 100 μl DMEM-H containing 20 mM glucose, 100 nM (0.1 μCi)
[3H]UDP-Gal, 5 mM MnCl2, and (except as indicated in D) 0.2 mg/ml α-lactalbumin.
Radioactive species were separated by HPLC. The data represent the mean ± SD from at least
three independent experiments performed in duplicates.
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Figure 2. 4βGT-catalized formation of lactose or N-acetyllactosamine
A, UDP-Gal but not UDP-Glc is a substrate of 4βGT. Incubations were as in Figure 1A, in the
presence of the indicated concentration of UDP-[3H]Gal or UDP-[3H]Glc. B, effect of N-
acetylglucosamine concentration on the conversion of 100 nM (0.1 μCi) UDP-[3H]Gal to [3H]
N-acetyllactosamine. Radioactive species were separated by HPLC. The data represent the
mean ± SD, n ≥ 3.
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Figure 3. Assessing UDP-Gal via UDP phosphorylation
The conversion of [γ32P]ATP to [γ32P]UTP was assessed by HPLC, as detailed in Methods.
A, UDP (10 nM) was incubated in the presence of 100 nM (0.2 μCi) [γ32P]ATP and the
indicated amount of NDPK. B, time course of the NDPK (0.1 U/ml)-catalyzed phosphorylation
of 10 nM UDP in the presence of 100 nM (0.2 μCi) [γ32P]ATP. C, the UDP calibration curve
was performed in the presence of 0.1 U/ml NDPK and 100 nM (0.2 μCi) [γ32P]ATP (5 min,
30°C). The reaction was lineal between 0–30 nM UDP (r2 = 0.9996), displaying a slope a value
of 0.93784 and an intercept b value of 0.07. D, UDP-Gal (at the indicated concentration) was
incubated for 30 min in the absence or presence of 0.002 U/ml 4βGT. At the end of this period,
NDPK and [γ32P]ATP were added for 5 min, as detailed in C. The reaction was lineal between
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0–30 nM UDP-Gal (a = 1.016, b = 0, and r2 = 0.9998). The data represent the mean ± SD, n
≥ 4. All incubations were performed in 100 μL DMEM-H supplemented with MnCl2 and α-
lactalbumin, as indicated in Figure 1. Background radioactivity (i.e., observed in the absence
of UDP-Gal and UDP) was subtracted from all data points to allow regression lines fitting to
origin.
Lazarowski Page 14













Figure 4. Enhanced UDP-Gal and UDP-Glc release from thrombin-stimulated 1321N1 human
astrocytoma cells
A, cells were rinsed and pre-incubated in 300 μl DMEM-H for 1 h, and thrombin (20 nM) was
subsequently added for 5 min. UDP-Gal and UDP-Glc present in the extracellular medium
were quantified, as described in Methods. The results represent the main value (± SD) from
two independent experiments performed in triplicate; (*) indicates significant differences
relative to control (p < 0.01, t-test). B, the stability of extracellular UDP-Gal and UDP-Glc on
1321N1 cells was assessed in cultures spiked with 0.5 μCi of the indicated radiotracer. Samples
were collected at the indicated times and the resulting [3H]species were analyzed by HPLC,
as described in Methods (mean ± SD, n = 4).
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Extracellular nucleotide levels on resting cells
Cells were rinsed and incubated undisturbed for 1 h in DMEM-H. The medium was collected and nucleotides
measured as indicated in Methods. The data (expressed in nM) represent the mean ± SEM from at least two
independent cultures with quadruplicate samples.
Cell type UDP-Gal UDP UDP-Glc ATP
HBE 1.5 ± 0.4 1.7 ± 0.2 4.6 ± 2.2 2.5 ± 0.5
MDCK 9.1 ± 3 8.2 ± 2 32 ± 4.2 1.2 ± 0.2
1321N1 < 0.5 2.4 ± 0.8 1.5 ± 0.8 4.2 ± 0.5
MCF-7 1.8 ± 0.5 2.7 ± 1.1 2.9 ± 0.4 6.1 ± 1.0
A549 0.7 ± 0.3 3.2 ± 0.6 2.3 ± 1.5 11 ± 3.3
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